Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 1990-02, Vol.17 (1), p.21-23
Main Authors: Cairncross, J. Gregory, Eisenhauer, Elizabeth A., Macdonald, David R., Rathbone, Michel P., Moore, Malcolm J., Sawka, Carol A., MacCormick, Ronald E., Kerr, Ian G.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Canada
Drug Evaluation
Female
Glioma - drug therapy
Humans
Injections, Intravenous
Male
Middle Aged
Original Articles
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Trimetrexate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473
cites cdi_FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473
container_end_page 23
container_issue 1
container_start_page 21
container_title Canadian journal of neurological sciences
container_volume 17
creator Cairncross, J. Gregory
Eisenhauer, Elizabeth A.
Macdonald, David R.
Rathbone, Michel P.
Moore, Malcolm J.
Sawka, Carol A.
MacCormick, Ronald E.
Kerr, Ian G.
description The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.
doi_str_mv 10.1017/S0317167100029966
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79672034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0317167100029966</cupid><sourcerecordid>79672034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473</originalsourceid><addsrcrecordid>eNp9kM1LAzEQxYMotX78AR6EnLytTja7SdebFK0FUbG9L9PsrEb2oyZZ0It_uyktXgRPA_Pe-w3zGDsTcClA6KsFSKGF0gIA0qJQao-NU8h1AiLP99l4Iycb_ZAdef8eTSpX2YiNUiEnkMsx-35-Q098PueLMFRfvK_50tmWgqNPDMRtx1_IDM5RF_hNh-sGfbCGzxrbt3jNHzHYvsOGT7Ez5Pi8i3IYYjKS4g4r5NPGdtZETyRj4_nM9cN6e--EHdRxRae7ecyWd7fL6X3y8DSbT28eEiMnMiRSFWlBE60qyA3oSWZWmMdfYIUaQRSyhrxS0ihZm0IJSsFkNQBmmrIi0_KYXWyxa9d_DORD2VpvqGmwo37wpS6UTkFm0Si2RuN67x3V5Tq2ge6rFFBuKi__VB4z5zv4sGqp-k3sOo663DGxXTlbvVL53g8ulub_of4AhcuKug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79672034</pqid></control><display><type>article</type><title>Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study</title><source>CUP_剑桥大学出版社过刊（国图购买）</source><creator>Cairncross, J. Gregory ; Eisenhauer, Elizabeth A. ; Macdonald, David R. ; Rathbone, Michel P. ; Moore, Malcolm J. ; Sawka, Carol A. ; MacCormick, Ronald E. ; Kerr, Ian G.</creator><creatorcontrib>Cairncross, J. Gregory ; Eisenhauer, Elizabeth A. ; Macdonald, David R. ; Rathbone, Michel P. ; Moore, Malcolm J. ; Sawka, Carol A. ; MacCormick, Ronald E. ; Kerr, Ian G.</creatorcontrib><description>The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.</description><identifier>ISSN: 0317-1671</identifier><identifier>EISSN: 2057-0155</identifier><identifier>DOI: 10.1017/S0317167100029966</identifier><identifier>PMID: 2138053</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - therapeutic use ; Canada ; Drug Evaluation ; Female ; Glioma - drug therapy ; Humans ; Injections, Intravenous ; Male ; Middle Aged ; Original Articles ; Quinazolines - administration &amp; dosage ; Quinazolines - therapeutic use ; Trimetrexate</subject><ispartof>Canadian journal of neurological sciences, 1990-02, Vol.17 (1), p.21-23</ispartof><rights>Copyright © Canadian Neurological Sciences Federation 1990</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473</citedby><cites>FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>161,314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2138053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cairncross, J. Gregory</creatorcontrib><creatorcontrib>Eisenhauer, Elizabeth A.</creatorcontrib><creatorcontrib>Macdonald, David R.</creatorcontrib><creatorcontrib>Rathbone, Michel P.</creatorcontrib><creatorcontrib>Moore, Malcolm J.</creatorcontrib><creatorcontrib>Sawka, Carol A.</creatorcontrib><creatorcontrib>MacCormick, Ronald E.</creatorcontrib><creatorcontrib>Kerr, Ian G.</creatorcontrib><title>Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study</title><title>Canadian journal of neurological sciences</title><addtitle>Can. j. neurol. sci</addtitle><description>The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Canada</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Glioma - drug therapy</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Articles</subject><subject>Quinazolines - administration &amp; dosage</subject><subject>Quinazolines - therapeutic use</subject><subject>Trimetrexate</subject><issn>0317-1671</issn><issn>2057-0155</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNp9kM1LAzEQxYMotX78AR6EnLytTja7SdebFK0FUbG9L9PsrEb2oyZZ0It_uyktXgRPA_Pe-w3zGDsTcClA6KsFSKGF0gIA0qJQao-NU8h1AiLP99l4Iycb_ZAdef8eTSpX2YiNUiEnkMsx-35-Q098PueLMFRfvK_50tmWgqNPDMRtx1_IDM5RF_hNh-sGfbCGzxrbt3jNHzHYvsOGT7Ez5Pi8i3IYYjKS4g4r5NPGdtZETyRj4_nM9cN6e--EHdRxRae7ecyWd7fL6X3y8DSbT28eEiMnMiRSFWlBE60qyA3oSWZWmMdfYIUaQRSyhrxS0ihZm0IJSsFkNQBmmrIi0_KYXWyxa9d_DORD2VpvqGmwo37wpS6UTkFm0Si2RuN67x3V5Tq2ge6rFFBuKi__VB4z5zv4sGqp-k3sOo663DGxXTlbvVL53g8ulub_of4AhcuKug</recordid><startdate>19900201</startdate><enddate>19900201</enddate><creator>Cairncross, J. Gregory</creator><creator>Eisenhauer, Elizabeth A.</creator><creator>Macdonald, David R.</creator><creator>Rathbone, Michel P.</creator><creator>Moore, Malcolm J.</creator><creator>Sawka, Carol A.</creator><creator>MacCormick, Ronald E.</creator><creator>Kerr, Ian G.</creator><general>Cambridge University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900201</creationdate><title>Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study</title><author>Cairncross, J. Gregory ; Eisenhauer, Elizabeth A. ; Macdonald, David R. ; Rathbone, Michel P. ; Moore, Malcolm J. ; Sawka, Carol A. ; MacCormick, Ronald E. ; Kerr, Ian G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Canada</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Glioma - drug therapy</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Articles</topic><topic>Quinazolines - administration &amp; dosage</topic><topic>Quinazolines - therapeutic use</topic><topic>Trimetrexate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cairncross, J. Gregory</creatorcontrib><creatorcontrib>Eisenhauer, Elizabeth A.</creatorcontrib><creatorcontrib>Macdonald, David R.</creatorcontrib><creatorcontrib>Rathbone, Michel P.</creatorcontrib><creatorcontrib>Moore, Malcolm J.</creatorcontrib><creatorcontrib>Sawka, Carol A.</creatorcontrib><creatorcontrib>MacCormick, Ronald E.</creatorcontrib><creatorcontrib>Kerr, Ian G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cairncross, J. Gregory</au><au>Eisenhauer, Elizabeth A.</au><au>Macdonald, David R.</au><au>Rathbone, Michel P.</au><au>Moore, Malcolm J.</au><au>Sawka, Carol A.</au><au>MacCormick, Ronald E.</au><au>Kerr, Ian G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study</atitle><jtitle>Canadian journal of neurological sciences</jtitle><addtitle>Can. j. neurol. sci</addtitle><date>1990-02-01</date><risdate>1990</risdate><volume>17</volume><issue>1</issue><spage>21</spage><epage>23</epage><pages>21-23</pages><issn>0317-1671</issn><eissn>2057-0155</eissn><abstract>The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>2138053</pmid><doi>10.1017/S0317167100029966</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0317-1671
ispartof Canadian journal of neurological sciences, 1990-02, Vol.17 (1), p.21-23
issn 0317-1671
2057-0155
language eng
recordid cdi_proquest_miscellaneous_79672034
source CUP_剑桥大学出版社过刊（国图购买）
subjects Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Canada
Drug Evaluation
Female
Glioma - drug therapy
Humans
Injections, Intravenous
Male
Middle Aged
Original Articles
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Trimetrexate
title Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A58%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20Study%20of%20Trimetrexate%20in%20Recurrent%20Anaplastic%20Glioma:%20National%20Cancer%20Institute%20of%20Canada%20Clinical%20Trials%20Group%20Study&rft.jtitle=Canadian%20journal%20of%20neurological%20sciences&rft.au=Cairncross,%20J.%20Gregory&rft.date=1990-02-01&rft.volume=17&rft.issue=1&rft.spage=21&rft.epage=23&rft.pages=21-23&rft.issn=0317-1671&rft.eissn=2057-0155&rft_id=info:doi/10.1017/S0317167100029966&rft_dat=%3Cproquest_cross%3E79672034%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c383t-36929e876d05c0784cba52650ba7a0193f05d63c63fc961e20c4f00a47e49473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79672034&rft_id=info:pmid/2138053&rft_cupid=10_1017_S0317167100029966&rfr_iscdi=true